Bariatric Surgery Beats GLP-1 Drugs in Head-to-Head Comparison
A comprehensive new study reveals whether weight-loss surgery or blockbuster GLP-1 drugs deliver better long-term results.
Read AnalysisNew Daily Pill Outperforms Semaglutide for Blood Sugar Control
A new once-daily oral drug called orforglipron may lower blood sugar levels more effectively than oral semaglutide.
Read AnalysisSemaglutide Significantly Reduces Heavy Drinking in Clinical Trial
A landmark clinical trial reveals that the popular drug semaglutide can dramatically curb heavy drinking days in patients with alcohol use disorder.
Read AnalysisWhat Happens After You Stop Semaglutide or Tirzepatide?
A new study reveals what actually happens to patients' weight a year after discontinuing popular GLP-1 medications.
Read AnalysisNew Daily Pill Shows Promise for Diabetes and Weight
A new phase 3 trial reveals that a daily oral pill called orforglipron could provide a highly effective, injection-free alternative for managing type 2 diabetes and body weight.
Read AnalysisNew Drug Combo Accelerates Fat Loss While Protecting Muscle
A new clinical trial shows that pairing the antibody bimagrumab with semaglutide leads to dramatic fat loss while helping preserve critical muscle mass.
Read AnalysisWomen Lose More Weight Than Men on GLP-1 Medications
A new analysis reveals that popular GLP-1 medications lead to significantly more percentage body mass reduction in women than in men.
Read AnalysisPopular GLP-1 Drug Fails to Slow Alzheimer's Disease Progression
Despite early promise, a large clinical trial reveals that the popular GLP-1 drug semaglutide does not slow down cognitive decline in early-stage Alzheimer's disease.
Read AnalysisSemaglutide May Outperform Tirzepatide for Heart Health in Obesity
A new real-world study suggests semaglutide provides greater protection against major cardiovascular events than tirzepatide in overweight adults with prior heart disease.
Read Analysis